GlassScriptPhysician profile
Nora Dohm Schuette
NPI 1548393564
$3,556.58
in general payments reported to CMS, 2019-2025
20 companies · $910 in 2025
The $910 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $503 · 2022: $317 · 2023: $748 · 2024: $1,078 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,710 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $580.87 | 2021-2025 | |
| Mdd US Operations, LLC | $461.36 | 2024-2025 | Apokyn, Gocovri, Xadago |
| Biogen, INC. | $447.71 | 2021-2023 | Tysabri, Vumerity, Plegridy |
| Emd Serono, INC. | $325.80 | 2021 | |
| Acadia Pharmaceuticals INC | $287.97 | 2024-2025 | Nuplazid |
| Tg Therapeutics, INC. | $237.71 | 2024-2025 | |
| Livanova USA, INC. | $197.53 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Boston Scientific Corporation | $187.63 | 2024 | |
| Insightec,INC | $165.10 | 2023 | Exablate |
| Genzyme Corporation | $142.09 | 2022 | |
| Lilly USA, LLC | $116.50 | 2024-2025 | Kisunla, Amyvid |
| Pfizer INC. | $93.26 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $82.59 | 2025 | Crexont |
| Otsuka America Pharmaceutical, INC. | $50.12 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $42.14 | 2025 | Austedo Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $40.70 | 2025 | Ampyra, Xeomin |
| Novartis Pharmaceuticals Corporation | $30.64 | 2022 | |
| Eisai INC. | $24.18 | 2025 | |
| Kyowa Kirin, INC. | $23.33 | 2024 | Nourianz |
| Lundbeck LLC | $19.35 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Schuette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.